Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs block open or inactivated voltage-sensitive L-type calcium channels in a use-dependent manner. They prevent repolarization until dissociating from the channel, which decreases the phase 4 depolarization rate. This action slows conduction in calcium-dependent tissues like the SA and AV nodes, ultimately reducing heart rate and suppressing ectopic beats.

Verapamil and diltiazem are both nondihydropyridine calcium channel blockers with similar mechanisms. However, diltiazem tends to cause less bradycardia than verapamil and has more impact on smooth muscle. Verapamil, the prototype drug, is a racemic mixture where the L-enantiomer has greater inhibitory effects on calcium influx and causes PR interval prolongation.

Intravenous verapamil causes significant adverse effects including bradycardia, hypotension, and peripheral edema. Oral administration reduces these side effects substantially. Additionally, when taken orally, verapamil undergoes first-pass hepatic metabolism, which affects its bioavailability and helps minimize systemic adverse effects while maintaining therapeutic benefits.

Class IV antiarrhythmic drugs are commonly used to treat re-entrant supraventricular tachycardia and to decrease the ventricular rate in atrial flutter and atrial fibrillation. Their ability to slow conduction in the SA and AV nodes and lengthen the effective refractory period makes them particularly effective for these calcium-dependent arrhythmias.

Class IV drugs slow conduction in the SA and AV nodes by blocking calcium influx, which decreases the phase 4 depolarization rate. This lengthens the effective refractory period and reduces heart rate. These electrophysiological changes suppress ectopic beats and help restore normal cardiac rhythm in patients with certain arrhythmias.

Verapamil and diltiazem can increase serum digoxin concentration, which may excessively slow the ventricular response in patients with atrial fibrillation. Close monitoring of patients' heart conditions and drug interactions is necessary. Caution should be exercised when using these drugs, particularly in combination with other cardiac medications.

Class IV antiarrhythmic drugs commonly cause bradycardia, hypotension, and peripheral edema. These adverse effects are more pronounced with intravenous administration than oral dosing. Caution should be exercised when using verapamil and diltiazem for ventricular tachycardia, as the risk of adverse effects is higher in this setting.